NBF 006
Alternative Names: NBF-006Latest Information Update: 22 Jun 2024
At a glance
- Originator Nitto Biopharma
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action Glutathione S-transferase pi expression inhibitors; Glutathione S-transferase pi inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 05 Apr 2024 Updated efficacy, adverse events and pharmacokinetics data from a phase I trial in Non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 12 Mar 2024 Nitto BioPharma completes a phase-I clinical trials in Non-small cell lung cancer, Colorectal cancer, Pancreatic cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03819387)
- 11 Oct 2023 Adverse events data from a phase I trial in Non-small cell lung cancer presented at the International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)